FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387380846> ?p ?o ?g. }

• W4387380846 abstract "Abstract Disclosure: A.W. Maciel: None. T. Freitas: None. D.L. Danilovic: None. G.F. Fagundes: None. F. Freitas-Castro: None. L. Santana: None. A. Guimaraes: None. A. Pio-Abreu: None. J. V. Silveira: None. F. Consolim-Colombo: None. L. Bortolotto: None. M.C. Fragoso: None. A. Latronico: None. L. Drager: None. B.B. Mendonca: None. A.O. Hoff: None. M.Q. Almeida: None. Introduction: Aldosterone excess can cause oxidative stress leading to DNA damage in vitro and in vivo. Single case reports demonstrated a coincidence of primary aldosteronism (PA) with different malignancies. A higher prevalence of thyroid nodules and non-toxic multinodular goiter was described in patients with PA compared to those with essential hypertension (HT). A single study showed an association between PA and papillary thyroid cancer (PTC), but without a paired control group. Objective: To assess PA prevalence in a transversal cohort of patients with PTC and HT compared to a paired control group with HT. Methods: In this cross-sectional case-control study, PA was investigated in all patients with PTC and HT (n= 114), regardless of HT severity, under active surveillance at a cancer institute from 2019 to 2022. The control group included 228 (2:1) age-, sex- and body mass index (BMI)-matched individuals from a retrospective cohort of HT previously investigated for PA from 2011 to 2022. Serum aldosterone and plasma direct renin concentrations were measured by a chemiluminescent immunoassay. A positive PA screening was defined by aldosterone ≥10 ng/dL and aldosterone to renin ratio ≥2 ng/dL/μUI/mL. Results: Age, sex and BMI were not statistically different between PTC and control groups, respectively (age 59.8 ± 12 vs. 58.9 ± 12.3 yrs, p= 0.67; 79% vs. 81% women, p= 0.67; BMI 30.7 ± 5.8 vs. 30.8 ± 6.5 Kg/m2, p= 0.98). PA was diagnosed in 35 out of 114 PTC patients with HT. The prevalence of PA in the PTC group (30.5%, confidence interval (IC) 22.6%-40.1%) was significantly higher when compared to the paired control group with HT (11.84%, CI 8.08%-16.93%; p&lt; 0.0001). Although PA prevalence was higher in the PTC group, only 20.2% had stage 3/resistant HT (vs. 38% in the control group, p= 0.003). The number of anti-hypertensive medications was lower in the PTC group compared to controls (2 drugs, 1 to 3 vs. 4 drugs, 3 to 5, respectively; p&lt; 0.001). When analyzing only PA patients in both groups, frequency of stage 3/resistant HT and number of medications were lower in the PTC group (p&lt; 0.001 and p&lt; 0.001, respectively). Although HT was more severe in PA patients without PTC, aldosterone and renin levels were not different in PA patients from PTC and control groups, respectively (p= 0.15 and p= 0.34). Conclusion: PA prevalence was strikingly high among patients with PTC and HT, supporting the recommendation of PA screening in this patient group, regardless of HT severity. Presentation: Thursday, June 15, 2023" @default.
• W4387380846 created "2023-10-06" @default.
• W4387380846 creator A5000647055 @default.
• W4387380846 creator A5004035589 @default.
• W4387380846 creator A5006947072 @default.
• W4387380846 creator A5007614613 @default.
• W4387380846 creator A5008550885 @default.
• W4387380846 creator A5015066019 @default.
• W4387380846 creator A5020707835 @default.
• W4387380846 creator A5023864103 @default.
• W4387380846 creator A5032013233 @default.
• W4387380846 creator A5036455850 @default.
• W4387380846 creator A5044408250 @default.
• W4387380846 creator A5056081475 @default.
• W4387380846 creator A5056961131 @default.
• W4387380846 creator A5061844889 @default.
• W4387380846 creator A5061947657 @default.
• W4387380846 creator A5064120511 @default.
• W4387380846 creator A5084285926 @default.
• W4387380846 date "2023-10-01" @default.
• W4387380846 modified "2023-10-18" @default.
• W4387380846 title "THU587 High Prevalence Of Primary Aldosteronism Diagnosis In Patients With Papillary Thyroid Cancer And Hypertension: A Cross-sectional Case-control Study" @default.
• W4387380846 doi "https://doi.org/10.1210/jendso/bvad114.585" @default.
• W4387380846 hasPublicationYear "2023" @default.
• W4387380846 type Work @default.
• W4387380846 citedByCount "0" @default.
• W4387380846 crossrefType "journal-article" @default.
• W4387380846 hasAuthorship W4387380846A5000647055 @default.
• W4387380846 hasAuthorship W4387380846A5004035589 @default.
• W4387380846 hasAuthorship W4387380846A5006947072 @default.
• W4387380846 hasAuthorship W4387380846A5007614613 @default.
• W4387380846 hasAuthorship W4387380846A5008550885 @default.
• W4387380846 hasAuthorship W4387380846A5015066019 @default.
• W4387380846 hasAuthorship W4387380846A5020707835 @default.
• W4387380846 hasAuthorship W4387380846A5023864103 @default.
• W4387380846 hasAuthorship W4387380846A5032013233 @default.
• W4387380846 hasAuthorship W4387380846A5036455850 @default.
• W4387380846 hasAuthorship W4387380846A5044408250 @default.
• W4387380846 hasAuthorship W4387380846A5056081475 @default.
• W4387380846 hasAuthorship W4387380846A5056961131 @default.
• W4387380846 hasAuthorship W4387380846A5061844889 @default.
• W4387380846 hasAuthorship W4387380846A5061947657 @default.
• W4387380846 hasAuthorship W4387380846A5064120511 @default.
• W4387380846 hasAuthorship W4387380846A5084285926 @default.
• W4387380846 hasBestOaLocation W43873808461 @default.
• W4387380846 hasConcept C126322002 @default.
• W4387380846 hasConcept C126894567 @default.
• W4387380846 hasConcept C134018914 @default.
• W4387380846 hasConcept C198710026 @default.
• W4387380846 hasConcept C2778525890 @default.
• W4387380846 hasConcept C2779761222 @default.
• W4387380846 hasConcept C2780221984 @default.
• W4387380846 hasConcept C2780233176 @default.
• W4387380846 hasConcept C2781461381 @default.
• W4387380846 hasConcept C526584372 @default.
• W4387380846 hasConcept C71924100 @default.
• W4387380846 hasConcept C72563966 @default.
• W4387380846 hasConcept C84393581 @default.
• W4387380846 hasConcept C90924648 @default.
• W4387380846 hasConceptScore W4387380846C126322002 @default.
• W4387380846 hasConceptScore W4387380846C126894567 @default.
• W4387380846 hasConceptScore W4387380846C134018914 @default.
• W4387380846 hasConceptScore W4387380846C198710026 @default.
• W4387380846 hasConceptScore W4387380846C2778525890 @default.
• W4387380846 hasConceptScore W4387380846C2779761222 @default.
• W4387380846 hasConceptScore W4387380846C2780221984 @default.
• W4387380846 hasConceptScore W4387380846C2780233176 @default.
• W4387380846 hasConceptScore W4387380846C2781461381 @default.
• W4387380846 hasConceptScore W4387380846C526584372 @default.
• W4387380846 hasConceptScore W4387380846C71924100 @default.
• W4387380846 hasConceptScore W4387380846C72563966 @default.
• W4387380846 hasConceptScore W4387380846C84393581 @default.
• W4387380846 hasConceptScore W4387380846C90924648 @default.
• W4387380846 hasIssue "Supplement_1" @default.
• W4387380846 hasLocation W43873808461 @default.
• W4387380846 hasOpenAccess W4387380846 @default.
• W4387380846 hasPrimaryLocation W43873808461 @default.
• W4387380846 hasRelatedWork W2017000262 @default.
• W4387380846 hasRelatedWork W2067336395 @default.
• W4387380846 hasRelatedWork W2116565214 @default.
• W4387380846 hasRelatedWork W2139412604 @default.
• W4387380846 hasRelatedWork W2149468526 @default.
• W4387380846 hasRelatedWork W2520425266 @default.
• W4387380846 hasRelatedWork W3022228189 @default.
• W4387380846 hasRelatedWork W3159540566 @default.
• W4387380846 hasRelatedWork W3211845144 @default.
• W4387380846 hasRelatedWork W4206801750 @default.
• W4387380846 hasVolume "7" @default.
• W4387380846 isParatext "false" @default.
• W4387380846 isRetracted "false" @default.
• W4387380846 workType "article" @default.